Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)

Reproductive Biology and Endocrinology

Volumn 4, Issue SUPPL. 1, 2006, Pages

  Chwalisz, Kristof ^a   Garg, Ramesh ^a   Brenner, Robert ^b   Slayden, Ov ^b   Winkel, Craig ^a   Elger, Walter ^c,d,e  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PAS Tech Gasanalytik GmbH   (Germany)

^d EnTec GmbH   (Germany)

^e NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 11BETA BENZALDOXIME DERIVATIVE; ALDOXIME; ANTIGESTAGEN; ASOPRISNIL; ASOPRISNIL ECAMATE; ESTROGEN; J 1042; J 912; J 956; ONAPRISTONE; PROGESTERONE RECEPTOR MODULATOR; PROMEGESTONE; SEX HORMONE; STEROID HORMONE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ZK 137316; ESTRANE DERIVATIVE; OXIME; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR;

AMENORRHEA; AREA UNDER THE CURVE; CANCER INHIBITION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENDOMETRIOSIS; ENDOMETRIUM CELL; ESTROGEN BLOOD LEVEL; EVIDENCE BASED MEDICINE; FEMALE; FOLLICULAR PHASE; HUMAN; IN VIVO STUDY; MITOSIS INHIBITION; MYOMETRIUM; NONHUMAN; OVULATION; PRIMATE; REVIEW; STEROID RELEASE; SYMPTOMATOLOGY; TISSUE SPECIFICITY; UTERUS BLEEDING; UTERUS FUNCTION; UTERUS MYOMA; ANIMAL; ANIMAL MODEL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENDOMETRIUM; LEIOMYOMA; METABOLISM; PHYSIOLOGY; SYNTHESIS; UDDER; UTERUS; UTERUS CANCER;

ANIMALIA; PRIMATES;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ENDOMETRIUM; ESTRENES; FEMALE; HUMANS; LEIOMYOMA; MAMMARY GLANDS, ANIMAL; MODELS, ANIMAL; MODELS, BIOLOGICAL; MODELS, MOLECULAR; ORGAN SPECIFICITY; OXIMES; PRIMATES; PROGESTERONE CONGENERS; RECEPTORS, PROGESTERONE; UTERINE HEMORRHAGE; UTERINE NEOPLASMS; UTERUS;

EID: 33750026445     PISSN: 14777827     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-4-S1-S8     Document Type: Review

References (54)

1. Allen WM, Wintersteiner O: Crystalline progesterone. Science 1934, 80:190-191.
2. Slotta KH, Rushig H, Fels E: Reindarstellung des Hormons aus dem Corpus luteum. Ber Chem Ges 1934, 67:1270-1273.
3. Butenandt A, Westphal U, Hohlweg W: Uber das Hormon des Corpus luteum. Hopper-Seyler's Z Physiol Chem 1934, 227:84-98.
4. Philibert D, Deraedt R, Teutsch G: RU 38486: a potent antiglucocorticoid in vivo. The VII International Congress of Pharmacology: 1981; Tokyo, Japan 1981.
5. Spitz IM: Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003, 68(10-13):981-993.
6. Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Eiger W: Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis [published erratum appears in Endocr Rev. 2005;26:703]. Endocr Rev 2005, 26(3):423-438.
7. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K: Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000, 65:713-723.
8. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K: Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003, 68(10-13):1019-1032.
9. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000, 65(10-11):741-751.
10. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L: The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod, 2005, 20:1090-1099.
11. Chwalisz K, Parker RL, Williamson S, Larsen L, McCrary K, Elger W: Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867 [abstract]. J Soc Gynecol Invest 2003, 10(Suppl 2):636.
12. Chwalisz K, Mattia-Goldberg C, Lee M, Elger W, Edmonds A: Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil [abstract]. Fertil Steril 2004, 82(Suppl 2):S83-S84.
13. Schubert G, Ring S, Erhardt B: Method for the production of 4-[17a-substituted-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (1E or 1Z)-oximes. In. US 2004.
14. Brenner RM, Rudolph L, Matrisian L, Slayden OD: Non-human primate models; artificial menstrual cycles, endometrial matrix metalloproteinases and s.c. endometrial grafts. Hum Reprod 1996, 11(Suppl 2):150-164.
15. Brenner RM, Nayak NR, Slayden OD, Critchley HO, Kelly RW: Premenstrual and menstrual changes in the macaque and human endometrium: relevance to endometriosis. Ann N Y Acad Sci 2002, 955:60-74. discussion 86-68, 396-406
16. Padykula HA: Regeneration in the primate uterus: the role of stem cells. Ann N Y Acad Sci 1991, 622:47-56.
17. Kelly RW, King AE, Critchley HO: Inflammatory mediators and endometrial function-focus on the perivascular cell. J Reprod Immunol 2002, 57(1-2):81-93.
18. Chwalisz K, Brenner R, Nayak N, Joskowiak D, Elger W: A comparison of the endometrial antiproliferative effects of a mesoprogestin (J1042) with the antiprogestins ZK 137 316 and ZK 230 211 in cynomolgus monkeys [Abstract]. J Soc Gynecol Invest 2000, 7:21A.
19. Brenner RM, Slayden OD, Garg R, Chwalisz K: Asoprisnil suppresses endometrial proliferation in cynomolgus macaques [abstract]. J Soc Gynecol Invest 2005, 12(Suppl):208A.
20. Brenner RM, Slayden OD, Rodgers WH, Critchley HO, Carroll R, Nie XJ, Mah K: Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum Reprod 2003, 18(6):1185-1193.
21. Chwalisz K, Larsen L, McCrary K, Edmonds A: Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. J Soc Gynecol Invest 2004, 11(Suppl 2(2)):320A-321A.
22. Chwalisz K, Larsen L, McCrary K, Edmonds A: Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on selected hormonal parameters in subjects with leiomyomata. Fertil Steril 2004, 82(Suppl 2):S306. abstract P-483
23. Noyes R, Hertig AT, Rock J: Dating the endometrial biopsy. Fertil Steril 1950, 1:3-25.
24. Williams AR, Critchley HO, Osei JHC, Chwalisz K: The selective progesterone receptor modulator asoprisnil inhibits glandular proliferation and induces consistent morphological effects in human endometrium [abstract]. J Soc Gynecol Investig 2006, 13(Suppl 2):261A-262A.
25. Clarke RB: Steroid receptors and proliferation in the human breast. Steroids 2003, 68(10-13):789-794.
26. Pike MC, Spicer DV: Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000, 7(2):73-83.
27. Hoffmann J, Lichtner RB, Fuhrmann U, Michna H, Parczyk K, Neef G, Chwalisz K, Schneider MR: Effects of progesterone receptor antagonists on breast cancer. London: Martin Dunitz Ltd; 2002.
28. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B: Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001, 4(1):42-48.
29. Conner P, Svane G, Azavedo E, Soderqvist G, Carlstrom K, Graser T, Walter F, von Schoultz B: Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril 2004, 81(6):1617-1623.
30. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999, 84(12):4559-4565.
31. Chwalisz K, Garg R, Brenner RM, Schubert G, Elger W: Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann NY Acad Sci 2002, 955:373-388. discussion 389-393, 396-406
32. Hickey M, Dwarte D, Fraser IS: Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod 2000, 15(7):1509-1514.
33. Hickey M, Fraser IS: The structure of endometrial microvessels. Hum Reprod 2000, 15(Suppl 3):57-66.
34. Simbar M, Manconi F, Markham R, Hickey M, Fraser IS: A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, norplant. Micron 2004, 35(7):589-595.
35. Slayden OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO, Baird DT, Brenner RM: Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab 2001, 86(6):2668-2679.
36. Brenner RM, Slayden OD, Critchley HO: Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 2002, 124(2):167-172.
37. Brenner RM, Slayden OD, Nayak NR, Baird DT, Critchley HO: A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists. Steroids 2003, 68(10-13):1033-1039.
38. Brenner RM, Slayden OD: Progesterone receptor antagonists and the endometrial antiproliferative effect. Semin Reprod Med 2005, 23(1):74-81.
39. Slayden OD, Brenner RM: Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab 2003, 88(2):946-949.
40. Chen W, Wang J, Ohara J, DeManno D, Chwalisz K, Maruo T: Selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured uterine leiomyoma cells but not in cultured normal myometrial cells [abstract]. Fertil Steril 2005, 84(Suppl 1):S152.
41. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-1, TGFβ and their receptors in cultured uterine leiomyoma cells http://humrep.oxfordjournals.org/ cgi/reprint/del035v1?maxtoshow= &HITS=10&hits=10&RESULTFORMAT=&fullxt=Maruo&searchid= 1&FIRSTINDEX=0&resourcetype=HWCIT]
42. Bagchi MK, Tsai SY, Tsai MJ, O'Malley BW: Progesterone enhances target gene transcription by receptor free of heat shock proteins hsp90, hsp56, and hsp70. Mol Cell Biol 1991, 11(10):4998-5004.
43. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992, 69(4):703-713.
44. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP: Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993, 7(10):1244-1255.
45. Smith CL, O'Malley BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004, 25(1):45-71.
46. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996, 10(10):1167-1177.
47. Hull ML, Prentice A, Wang DY, Butt RP, Phillips SC, Smith SK, Charnock-Jones DS: Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod 2004.
48. Chen JD, Evans RM: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995, 377(6548):454-457.
49. Onate SA, Tsai SY, Tsai MJ, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270(5240):1354-1357.
50. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997, 11(6):693-705.
51. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP: The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 1998, 18(3):1369-1378.
52. Wagner BL, Pollio G, Leonhardt S, Wani MC, Lee DY, Imhof MO, Edwards DP, Cook CE, McDonnell DP: 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc Natl Acad Sci USA 1996, 93(16):8739-8744.
53. Melvin V, Perez M, Chwalisz K, Edwards D: Mechanism of action of the selective progesterone receptor modulator asoprisnil [abstract]. In The Endocrine Society's 87th Annual Meeting: 4-7 June 2005 San Diego, CA: The Endocrine Society, 2005:613. Abstract P613-284
54. Schubert G, Elger W, Kaufmann G, Schneider B, Reddersen G, Chwalisz K: Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 2005, 23(1):58-73.